720P Randomised phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Interim analysis (IA) of SURF study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.792 ◽

2020 ◽

Vol 31 ◽

pp. S565-S566

Author(s):

A. Thiery-Vuillemin ◽

G. Gravis ◽

F. Constans Schlurmann ◽

E. Bompas ◽

F. Rolland ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Interim Analysis ◽

Phase Ii Study ◽

Dose Administration ◽

Administration Regimen

Download Full-text

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

Trials ◽

10.1186/s13063-018-2613-8 ◽

2018 ◽

Vol 19 (1) ◽

Cited By ~ 4

Author(s):

Guillaume Mouillet ◽

Marie-Justine Paillard ◽

Tristan Maurina ◽

Dewi Vernerey ◽

Thierry Nguyen Tan Hon ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Phase Ii Study ◽

Open Label ◽

Dose Administration ◽

Multicentre Phase ◽

Administration Regimen

Download Full-text

Surf: Open label, randomized multi-centre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma (mRCC)

Annals of Oncology ◽

10.1093/annonc/mdw373.70 ◽

2016 ◽

Vol 27 ◽

pp. vi292

Author(s):

G. Mouillet ◽

T. Maurina ◽

M.-J. Paillard ◽

P. Montcuquet ◽

T. Nguyen Tan Hon ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Phase Ii Study ◽

Open Label ◽

Dose Administration ◽

Dose Modification ◽

Administration Regimen

Download Full-text

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2

Annals of Oncology ◽

10.1093/annonc/mds399 ◽

2012 ◽

Vol 23 ◽

pp. ix258 ◽

Cited By ~ 24

Author(s):

A. Ravaud ◽

C. Barrios ◽

Ö. Anak ◽

D. Pelov ◽

A. Louveau ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Phase Ii Study ◽

Interferon Alfa ◽

First Line ◽

Randomized Phase Ii

Download Full-text

Cyclic Interf eron Alpha Treatment in Metastatic Renal Cell Carcinoma: Results of a Phase II Study and Review of the Literature

Urologia Internationalis ◽

10.1159/000282937 ◽

1997 ◽

Vol 58 (1) ◽

pp. 8-12 ◽

Cited By ~ 4

Author(s):

Georg Hofmockel ◽

Winfried Tack ◽

Hubert G.W. Frohmüller

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Phase Ii Study ◽

Review Of The Literature

Download Full-text

A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2012.12.002 ◽

2013 ◽

Vol 11 (2) ◽

pp. 100-106 ◽

Cited By ~ 20

Author(s):

Lauren C. Harshman ◽

Sarah Barbeau ◽

Alex McMillian ◽

Sandy Srinivas

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Phase Ii Study

Download Full-text

Immunochemotherapy with interleukin-2, interferon- α and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study

British Journal of Cancer ◽

10.1054/bjoc.1999.0997 ◽

2000 ◽

Vol 82 (4) ◽

pp. 772-776 ◽

Cited By ~ 40

Author(s):

C M L van Herpen ◽

R L H Jansen ◽

W H J Kruit ◽

K Hoekman ◽

G Groenewegen ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Phase Ii Study ◽

Interleukin 2 ◽

Interferon Α ◽

Multicenter Phase

Download Full-text

Interferon-α, 5-FU and prednisone in metastatic renal cell carcinoma: A phase II study

Annals of Oncology ◽

10.1093/oxfordjournals.annonc.a058801 ◽

1994 ◽

Vol 5 (3) ◽

pp. 245-248 ◽

Cited By ~ 18

Author(s):

H. Haarstad ◽

A.-B. Jacobsen ◽

S.A. Schjølseth ◽

T. Risberg ◽

S.D. Fosså

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Phase Ii Study ◽

Interferon Α

Download Full-text

Phase II study of vinflunine in patients with metastatic renal cell carcinoma

Investigational New Drugs ◽

10.1007/s10637-006-6437-0 ◽

2006 ◽

Vol 24 (5) ◽

pp. 429-434 ◽

Cited By ~ 12

Author(s):

D. Goldstein ◽

S. P. Ackland ◽

D. R. Bell ◽

I. N. Olver ◽

I. D. Davis ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Phase Ii Study

Download Full-text

4504 ORAL A phase II study of continuous daily administration of sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC) – final results

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71135-7 ◽

2007 ◽

Vol 5 (4) ◽

pp. 299-300 ◽

Cited By ~ 2

Author(s):

B. Escudier ◽

S. Srinivas ◽

J. Roigas ◽

S. Gillessen ◽

U. Harmenberg ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Phase Ii Study ◽

Daily Administration

Download Full-text

Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma

Urologic Oncology Seminars and Original Investigations ◽

10.1016/j.urolonc.2006.03.004 ◽

2006 ◽

Vol 24 (6) ◽

pp. 487-491 ◽

Cited By ~ 6

Author(s):

Lance C. Pagliaro ◽

Cherie A. Perez ◽

Shi-Ming Tu ◽

Danai D. Daliani

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Phase Ii Study ◽

Single Agent ◽

Single Agent Therapy

Download Full-text